Liu W, Holdsworth C, Ye L. Synthesis of molecularly imprinted polymers using a functionalized initiator for chiral-selective recognition of propranolol. Chirality. 2020;32:370-377 pubmed publisher

Fornells E, Fuguet E, Mañé M, Ruiz R, Box K, Bosch E, et al. Effect of vinylpyrrolidone polymers on the solubility and supersaturation of drugs; a study using the Cheqsol method. Eur J Pharm Sci. 2018;117:227-235 pubmed publisher

Okamoto H, Hamaguchi R, Kuroda Y. Hydrophilic interaction chromatography with a focus on the drug-phosphate interaction in drug screening to determine the phospholipidosis induction risk. J Chromatogr B Analyt Technol Biomed Life Sci. 2017;1051:33-40 pubmed publisher

Teixeira Castro A, Jalles A, Esteves S, Kang S, da Silva Santos L, Silva Fernandes A, et al. Serotonergic signalling suppresses ataxin 3 aggregation and neurotoxicity in animal models of Machado-Joseph disease. Brain. 2015;138:3221-37 pubmed publisher

Alvarez Segura T, Gómez Díaz A, Ortiz Bolsico C, Torres Lapasió J, García Alvarez Coque M. A chromatographic objective function to characterise chromatograms with unknown compounds or without standards available. J Chromatogr A. 2015;1409:79-88 pubmed publisher

Peris García E, Ortiz Bolsico C, Baeza Baeza J, García Álvarez Coque M. Isocratic and gradient elution in micellar liquid chromatography with Brij-35. J Sep Sci. 2015;38:2059-67 pubmed publisher

Nakamura Y, Ishii J, Kondo A. Applications of yeast-based signaling sensor for characterization of antagonist and analysis of site-directed mutants of the human serotonin 1A receptor. Biotechnol Bioeng. 2015;112:1906-15 pubmed publisher

Al Majed A, Hefnawy M, Mohammed M, Attia S, Lehmann J. Selective microemulsion liquid chromatography analysis of dopamine receptor antagonist LE300 and its N-methyl metabolite in mouse sera by using a monolithic silica column. J Chromatogr B Analyt Technol Biomed Life Sci. 2015;989:104-11 pubmed publisher

Santos M, Tavares I, Boralli V, Figueiredo E. Direct doping analysis of beta-blocker drugs from urinary samples by on-line molecularly imprinted solid-phase extraction coupled to liquid chromatography/mass spectrometry. Analyst. 2015;140:2696-703 pubmed publisher

Galea C, Mangelings D, Heyden Y. Method development for impurity profiling in SFC: The selection of a dissimilar set of stationary phases. J Pharm Biomed Anal. 2015;111:333-43 pubmed publisher

Rocchi S, Rocco A, Pesek J, Matyska M, Capitani D, Fanali S. Enantiomers separation by nano-liquid chromatography: use of a novel sub-2 μm vancomycin silica hydride stationary phase. J Chromatogr A. 2015;1381:149-59 pubmed publisher

Ubeda Torres M, Ortiz Bolsico C, García Alvarez Coque M, Ruiz Angel M. Gaining insight in the behaviour of imidazolium-based ionic liquids as additives in reversed-phase liquid chromatography for the analysis of basic compounds. J Chromatogr A. 2015;1380:96-103 pubmed publisher

Udy A, Jarrett P, Stuart J, Lassig Smith M, Starr T, Dunlop R, et al. Determining the mechanisms underlying augmented renal drug clearance in the critically ill: use of exogenous marker compounds. Crit Care. 2014;18:657 pubmed publisher

Mandic M, Drinovec L, Glisic S, Veljkovic N, Nøhr J, Vrecl M. Demonstration of a direct interaction between β2-adrenergic receptor and insulin receptor by BRET and bioinformatics. PLoS ONE. 2014;9:e112664 pubmed publisher

Freitas A, Egea J, Buendia I, Navarro E, Rada P, Cuadrado A, et al. Agmatine induces Nrf2 and protects against corticosterone effects in hippocampal neuronal cell line. Mol Neurobiol. 2015;51:1504-19 pubmed publisher

Hsieh M, Chau L, Hon Y. Single-step approach for fabrication of vancomycin-bonded silica monolith as chiral stationary phase. J Chromatogr A. 2014;1358:208-16 pubmed publisher

Periat A, Kohler I, Bugey A, Bieri S, Versace F, Staub C, et al. Hydrophilic interaction chromatography versus reversed phase liquid chromatography coupled to mass spectrometry: effect of electrospray ionization source geometry on sensitivity. J Chromatogr A. 2014;1356:211-20 pubmed publisher

Vlčková H, Ježková K, Stětková K, Tomšíková H, Solich P, Novakova L. Study of the retention behavior of small polar molecules on different types of stationary phases used in hydrophilic interaction liquid chromatography. J Sep Sci. 2014;37:1297-307 pubmed publisher

Agius A, Jones N, Muscat R. Serial blood serotonin levels in a randomized controlled trial comparing the efficacy of low-dose amitriptyline, amitriptyline with pindolol and surrogate placebo in patients with chronic tension-type facial pain. Rhinology. 2013;51:236-42 pubmed publisher

Tan C, Tan E, Luo B, Huang C, Loo J, Choong C, et al. SMAD3 deficiency promotes inflammatory aortic aneurysms in angiotensin II-infused mice via activation of iNOS. J Am Heart Assoc. 2013;2:e000269 pubmed publisher

Agius A, Jones N, Muscat R. A Randomized Controlled Trial comparing the efficacy of low-dose amitriptyline, amitriptyline with pindolol and surrogate placebo in the treatment of chronic tension-type facial pain. Rhinology. 2013;51:143-53 pubmed publisher

Wang C, Jiang Y, Ma J, Wu H, Wacker D, KATRITCH V, et al. Structural basis for molecular recognition at serotonin receptors. Science. 2013;340:610-4 pubmed publisher

Skelin I, Fikre Merid M, Diksic M. Both acute and subchronic treatments with pindolol, a 5-HT(1A) and ?? and ?? adrenoceptor antagonist, elevate regional serotonin synthesis in the rat brain: an autoradiographic study. Neurochem Int. 2012;61:1417-23 pubmed publisher

Erkinaro T, Haapsamo M, Kavasmaa T, Mäkikallio K, Acharya G, Rasanen J. Fetal cardiac function after labetalol or pindolol for maternal hypertension in a sheep model of increased placental vascular resistance. Eur J Obstet Gynecol Reprod Biol. 2013;166:18-22 pubmed publisher

Saijo T, Maeda J, Okauchi T, Maeda J, Morio Y, Kuwahara Y, et al. Presynaptic selectivity of a ligand for serotonin 1A receptors revealed by in vivo PET assays of rat brain. PLoS ONE. 2012;7:e42589 pubmed publisher

Morante Zarcero S, Sierra I. Simultaneous enantiomeric determination of propranolol, metoprolol, pindolol, and atenolol in natural waters by HPLC on new polysaccharide-based stationary phase using a highly selective molecularly imprinted polymer extraction. Chirality. 2012;24:860-6 pubmed publisher

Belal F, Sharaf el Din M, Aly F, Hefnawy M, el Awady M. Fluorometric determination of bopindolol and celiprolol in pharmaceutical preparations and biological fluids. J Fluoresc. 2012;22:1141-50 pubmed publisher

Martiny K, Lunde M, Bech P, Plenge P. A short-term double-blind randomized controlled pilot trial with active or placebo pindolol in patients treated with venlafaxine for major depression. Nord J Psychiatry. 2012;66:147-54 pubmed publisher

Abdelkrim M, Mallem M, Chatagnon G, Gogny M, Desfontis J, Noireaud J. Autoantibodies against cardiac β(1)-adrenoceptor do not affect the low-affinity state β(1)-adrenoceptor-mediated inotropy in rat cardiomyocytes. Can J Physiol Pharmacol. 2012;90:407-14 pubmed publisher

Silva S, Ribeiro C. Tachyphylaxis to the sumatriptan-induced contractile effect in the human uterine artery but not in human cerebral blood vessels: pharmacological demonstration of the 5-HT(1B) receptor functionality loss. Pharmacology. 2012;89:29-36 pubmed publisher

Jin Y, Chen C, Meng L, Chen J, Li M, Zhu Z. Simultaneous and sensitive capillary electrophoretic enantioseparation of three ?-blockers with the combination of achiral ionic liquid and dual CD derivatives. Talanta. 2012;89:149-54 pubmed publisher

Liu Z, Shi Q, Ding D, Kelly R, Fang H, Tong W. Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). PLoS Comput Biol. 2011;7:e1002310 pubmed publisher

Terao T. Can pindolol really enhance antidepressant effect?. J Clin Psychiatry. 2011;72:1558; author reply 1558 pubmed publisher

Newman W, McDermott B. Beta blockers for violence prophylaxis: case reports. J Clin Psychopharmacol. 2011;31:785-7 pubmed publisher

Bao J, Krylova S, Wilson D, Reinstein O, Johnson P, Krylov S. Kinetic capillary electrophoresis with mass-spectrometry detection (KCE-MS) facilitates label-free solution-based kinetic analysis of protein-small molecule binding. Chembiochem. 2011;12:2551-4 pubmed publisher

Block F, Dafotakis M. [Drug-induced tremor]. Fortschr Neurol Psychiatr. 2011;79:570-5 pubmed publisher

Miller J, Tate C. Engineering an ultra-thermostable β(1)-adrenoceptor. J Mol Biol. 2011;413:628-38 pubmed publisher

Baker J, Adams L, Salchow K, Mistry S, Middleton R, Hill S, et al. Synthesis and characterization of high-affinity 4,4-difluoro-4-bora-3a,4a-diaza-s-indacene-labeled fluorescent ligands for human ?-adrenoceptors. J Med Chem. 2011;54:6874-87 pubmed publisher

Bode M, Gravestock D, Moleele S, van der Westhuyzen C, Pelly S, Steenkamp P, et al. Imidazo[1,2-a]pyridin-3-amines as potential HIV-1 non-nucleoside reverse transcriptase inhibitors. Bioorg Med Chem. 2011;19:4227-37 pubmed publisher

Goral V, Jin Y, Sun H, Ferrie A, Wu Q, Fang Y. Agonist-directed desensitization of the β2-adrenergic receptor. PLoS ONE. 2011;6:e19282 pubmed publisher

Zielińska Pisklak M, Pisklak D, Wawer I. 1H and 13C NMR characteristics of ?-blockers. Magn Reson Chem. 2011;49:284-90 pubmed publisher

Gozalbes R, Jacewicz M, Annand R, Tsaioun K, Pineda Lucena A. QSAR-based permeability model for drug-like compounds. Bioorg Med Chem. 2011;19:2615-24 pubmed publisher

Sela V, Biesdorf C, Ramos D, Zangrossi H, Graeff F, Audi E. Serotonin-1A receptors in the dorsal periaqueductal gray matter mediate the panicolytic-like effect of pindolol and paroxetine combination in the elevated T-maze. Neurosci Lett. 2011;495:63-6 pubmed publisher

Herold F, Chodkowski A, Izbicki Ł, Turło J, Dawidowski M, Kleps J, et al. Novel 4-aryl-pyrido[1,2-c]pyrimidines with dual SSRI and 5-HT(1A) activity. part 3. Eur J Med Chem. 2011;46:142-9 pubmed publisher

Portella M, de Diego Adeliño J, Ballesteros J, Puigdemont D, Oller S, Santos B, et al. Can we really accelerate and enhance the selective serotonin reuptake inhibitor antidepressant effect? A randomized clinical trial and a meta-analysis of pindolol in nonresistant depression. J Clin Psychiatry. 2011;72:962-9 pubmed publisher

Buttar D, Colclough N, Gerhardt S, Macfaul P, Phillips S, Plowright A, et al. A combined spectroscopic and crystallographic approach to probing drug-human serum albumin interactions. Bioorg Med Chem. 2010;18:7486-96 pubmed publisher

Ekins S, Williams A, Xu J. A predictive ligand-based Bayesian model for human drug-induced liver injury. Drug Metab Dispos. 2010;38:2302-8 pubmed publisher

Sela V, Roncon C, Zangrossi H, Graeff F, Audi E. Pindolol potentiates the panicolytic effect of paroxetine in the elevated T-maze. Life Sci. 2010;87:445-50 pubmed publisher

Del Giaccio A, Eblen Zajjur A. Cardiovascular drugs in human mechanical nociception: digoxin, amlodipine, propranolol, pindolol and atenolol. Invest Clin. 2010;51:77-86 pubmed

Gozalbes R, Pineda Lucena A. QSAR-based solubility model for drug-like compounds. Bioorg Med Chem. 2010;18:7078-84 pubmed publisher

Balaraman G, Bhattacharya S, Vaidehi N. Structural insights into conformational stability of wild-type and mutant beta1-adrenergic receptor. Biophys J. 2010;99:568-77 pubmed publisher

Greene N, Fisk L, Naven R, Note R, Patel M, Pelletier D. Developing structure-activity relationships for the prediction of hepatotoxicity. Chem Res Toxicol. 2010;23:1215-22 pubmed publisher

Hysek C, Vollenweider F, Liechti M. Effects of a beta-blocker on the cardiovascular response to MDMA (Ecstasy). Emerg Med J. 2010;27:586-9 pubmed publisher

Giacomini K, Huang S, Tweedie D, Benet L, Brouwer K, Chu X, et al. Membrane transporters in drug development. Nat Rev Drug Discov. 2010;9:215-36 pubmed publisher

Varma M, Obach R, Rotter C, Miller H, Chang G, Steyn S, et al. Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination. J Med Chem. 2010;53:1098-108 pubmed publisher

Guerra A, Campillo N, Paez J. Neural computational prediction of oral drug absorption based on CODES 2D descriptors. Eur J Med Chem. 2010;45:930-40 pubmed publisher

Kruhlak N, Choi S, Contrera J, Weaver J, Willard J, Hastings K, et al. Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models. Toxicol Mech Methods. 2008;18:217-27 pubmed publisher

Fridén M, Winiwarter S, Jerndal G, Bengtsson O, Wan H, Bredberg U, et al. Structure-brain exposure relationships in rat and human using a novel data set of unbound drug concentrations in brain interstitial and cerebrospinal fluids. J Med Chem. 2009;52:6233-43 pubmed publisher

Langham J, Cleves A, Spitzer R, Kirshner D, Jain A. Physical binding pocket induction for affinity prediction. J Med Chem. 2009;52:6107-25 pubmed publisher

Du Cuny L, Song Z, Moses S, Powis G, Mash E, Meuillet E, et al. Computational modeling of novel inhibitors targeting the Akt pleckstrin homology domain. Bioorg Med Chem. 2009;17:6983-92 pubmed publisher

Varma M, Feng B, Obach R, Troutman M, Chupka J, Miller H, et al. Physicochemical determinants of human renal clearance. J Med Chem. 2009;52:4844-52 pubmed publisher

Bard B, Carrupt P, Martel S. Lipophilicity of basic drugs measured by hydrophilic interaction chromatography. J Med Chem. 2009;52:3416-9 pubmed publisher

Wan H, Ahman M, Holmén A. Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs. J Med Chem. 2009;52:1693-700 pubmed publisher

Whale R, Terao T, Cowen P, Freemantle N, Geddes J. Pindolol augmentation of serotonin reuptake inhibitors for the treatment of depressive disorder: a systematic review. J Psychopharmacol. 2010;24:513-20 pubmed publisher

Li H, Sun J, Sui X, Liu J, Yan Z, Liu X, et al. First-principle, structure-based prediction of hepatic metabolic clearance values in human. Eur J Med Chem. 2009;44:1600-6 pubmed publisher

Groszek G, Bednarski M, Dybała M, Filipek B. Synthesis and adrenolytic activity of 1-(1H-indol-4-yloxy)-3-{[2-(2-methoxyphenoxy)ethyl]amino}propan-2-ol and its enantiomers. Part 1. Eur J Med Chem. 2009;44:809-17 pubmed publisher

Obach R, Lombardo F, Waters N. Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Drug Metab Dispos. 2008;36:1385-405 pubmed publisher

Henchoz Y, Guillarme D, Rudaz S, Veuthey J, Carrupt P. High-throughput log P determination by ultraperformance liquid chromatography: a convenient tool for medicinal chemists. J Med Chem. 2008;51:396-9 pubmed publisher

Krushinski J, Schaus J, Thompson D, Calligaro D, Nelson D, Luecke S, et al. Indoloxypropanolamine analogues as 5-HT(1A) receptor antagonists. Bioorg Med Chem Lett. 2007;17:5600-4 pubmed

Abraham M, Ibrahim A, Acree W. Air to lung partition coefficients for volatile organic compounds and blood to lung partition coefficients for volatile organic compounds and drugs. Eur J Med Chem. 2008;43:478-85 pubmed

Fujikawa M, Nakao K, Shimizu R, Akamatsu M. QSAR study on permeability of hydrophobic compounds with artificial membranes. Bioorg Med Chem. 2007;15:3756-67 pubmed

Diamandis P, Wildenhain J, Clarke I, Sacher A, Graham J, Bellows D, et al. Chemical genetics reveals a complex functional ground state of neural stem cells. Nat Chem Biol. 2007;3:268-73 pubmed

Artigas F, Adell A, Celada P. Pindolol augmentation of antidepressant response. Curr Drug Targets. 2006;7:139-47 pubmed

Morphy R, Rankovic Z. Designed multiple ligands. An emerging drug discovery paradigm. J Med Chem. 2005;48:6523-43 pubmed

Caron G, Ermondi G. Calculating virtual log P in the alkane/water system (log P(N)(alk)) and its derived parameters deltalog P(N)(oct-alk) and log D(pH)(alk). J Med Chem. 2005;48:3269-79 pubmed

Matsson P, Bergström C, Nagahara N, Tavelin S, Norinder U, Artursson P. Exploring the role of different drug transport routes in permeability screening. J Med Chem. 2005;48:604-13 pubmed

Segrave R, Nathan P. Pindolol augmentation of selective serotonin reuptake inhibitors: accounting for the variability of results of placebo-controlled double-blind studies in patients with major depression. Hum Psychopharmacol. 2005;20:163-74 pubmed

Brousse G, Schmitt A, Chereau I, Eschalier A, Dubray C, Llorca P. [Interest of the use of pindolol in the treatment of depression: review]. Encephale. 2003;29:338-50 pubmed

Kinney G, Taber M, Gribkoff V. The augmentation hypothesis for improvement of antidepressant therapy: is pindolol a suitable candidate for testing the ability of 5HT1A receptor antagonists to enhance SSRI efficacy and onset latency?. Mol Neurobiol. 2000;21:137-52 pubmed

Artigas F, Celada P, Laruelle M, Adell A. How does pindolol improve antidepressant action?. Trends Pharmacol Sci. 2001;22:224-8 pubmed

Olver J, Cryan J, Burrows G, Norman T. Pindolol augmentation of antidepressants: a review and rationale. Aust N Z J Psychiatry. 2000;34:71-9 pubmed

Martinez D, Broft A, Laruelle M. Pindolol augmentation of antidepressant treatment: recent contributions from brain imaging studies. Biol Psychiatry. 2000;48:844-53 pubmed

Ichikawa J, Meltzer H. The effect of ipsapirone and S(-)-pindolol on dopamine release in rat striatum and nucleus accumbens. Brain Res. 1999;842:445-51 pubmed

Fornal C, Martin F, Metzler C, Jacobs B. Pindolol suppresses serotonergic neuronal activity and does not block the inhibition of serotonergic neurons produced by 8-hydroxy-2-(di-n-propylamino)tetralin in awake cats. J Pharmacol Exp Ther. 1999;291:229-38 pubmed

Millan M, Gobert A. (-)-Pindolol increases dialysate concentrations of dopamine and noradrenaline, but not serotonin, in the frontal cortex of freely-moving rats. Neuropharmacology. 1999;38:909-12 pubmed

Puzantian T, Kawase K. Does the addition of pindolol accelerate or enhance the response to selective serotonin reuptake inhibitor antidepressants?. Pharmacotherapy. 1999;19:205-12 pubmed

McAskill R, Mir S, Taylor D. Pindolol augmentation of antidepressant therapy. Br J Psychiatry. 1998;173:203-8 pubmed

Blier P, Bergeron R. The use of pindolol to potentiate antidepressant medication. J Clin Psychiatry. 1998;59 Suppl 5:16-23; discussion 24-5 pubmed

Watkins D, Lawrence A, Lewis S, Jarrott B. Loss of [125I]-pindolol binding to beta-adrenoceptors on rat nodose ganglion after chronic isoprenaline treatment. J Auton Nerv Syst. 1996;60:12-6 pubmed

Krupp P, Fanchamps A. Pindolol: experience gained in 10 years of safety monitoring. Am Heart J. 1982;104:486-90 pubmed

Gonasun L. Antihypertensive effects of pindolol. Am Heart J. 1982;104:374-87 pubmed

Frishman W. Drug therapy. Pindolol: a new beta-adrenoceptor antagonist with partial agonist activity. N Engl J Med. 1983;308:940-4 pubmed

Fanchamps A. Therapeutic trials of pindolol in hypertension: comparison and combination with other drugs. Am Heart J. 1982;104:388-406 pubmed

Aellig W. Clinical pharmacology of pindolol. Am Heart J. 1982;104:346-56 pubmed

Duner H. Reversibility of structural changes in the resistance vessels in hypertension: a review of studies with pindolol. Br J Clin Pharmacol. 1987;24 Suppl 1:51S-54S pubmed

Herpin D, Guillard O, Piriou A, Amiel A, Boutaud P, Ciber M, et al. [Comparative effects of pindolol and atenolol on blood pressure and lipids in mild to moderate arterial hypertension]. Ann Med Interne (Paris). 1988;139:484-7 pubmed

Aellig W, Clark B. Is the ISA of pindolol beta 2-adrenoceptor selective?. Br J Clin Pharmacol. 1987;24 Suppl 1:21S-28S pubmed

. Effects of pindolol, or a pindolol/clopamide combination preparation, on plasma lipid levels in essential hypertension. Hunter Hypertension Research Group. Med J Aust. 1989;150:646, 648, 651-2 pubmed